Semaglutide week one: what the appetite loss actually means

What did @lucyarnisonx actually say?

Here's the honest answer: the transcript doesn't match the caption. The words spoken in the video are song lyrics, not a direct verbal account of semaglutide use. So the factual claims worth examining come entirely from the caption, which reads: first week of semaglutide, noticing a difference, "literally didn't even wanna eat anything else," and a self-identification as a binge eater.

That's actually a meaningful set of claims, even if they weren't spoken aloud. The caption describes appetite suppression kicking in during week one and implies the drug is already affecting eating behavior. She also frames this as a departure from a binge-eating pattern, which raises specific clinical questions worth unpacking. We'll treat the caption as the primary content here, because that's where the substance lives.

Does the science back this up?

On appetite suppression in week one: yes, broadly. GLP-1 receptor agonists like semaglutide work by slowing gastric emptying, reducing hunger signaling via the hypothalamus, and increasing satiety hormones. These mechanisms are active from the first dose, even at low starting doses.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed significant reductions in appetite and caloric intake in participants on semaglutide 2.4mg weekly. While that trial measured outcomes over 68 weeks, appetite changes were reported early. A smaller pharmacodynamic study by Flint et al. (2000, Journal of Clinical Investigation) on GLP-1 infusion confirmed acute appetite suppression effects. So the claim that she "didn't even wanna eat anything else" in week one is consistent with how the drug behaves physiologically. That part checks out.

What did they get wrong (or right)?

She got the appetite suppression timeline right. That's worth saying plainly. Week-one appetite changes are documented and biologically plausible, not just placebo or wishful thinking.

Where it gets complicated is the binge-eating framing. Semaglutide's effect on binge eating disorder (BED) is an active and promising area of research, but it's not settled. A 2023 randomized trial by Giel et al. published in Nature Medicine found reductions in binge-eating episodes with GLP-1 agonists, partly attributed to effects on reward circuitry and dopamine signaling. However, reduced appetite is not the same as treating BED. Binge eating has compulsive, psychological components that appetite suppression alone doesn't address. Framing semaglutide as fixing a binge-eating pattern because you're not hungry is an oversimplification. It also risks giving people with clinically diagnosed BED a false sense that a medication replaces behavioral or psychological support, which the evidence does not support.

What should you actually know?

Early appetite suppression on semaglutide is real and well-documented. But a few things the video doesn't mention matter a lot.

• Starting doses are low for a reason. Nausea, vomiting, and GI distress are common early side effects. Not feeling like eating in week one could reflect genuine GLP-1 satiety signaling or nausea-related appetite suppression. Those are different things with different implications.
• Semaglutide is not approved specifically for binge eating disorder. Anyone self-identifying as a binge eater should have that assessed properly before and during treatment.
• The STEP trials used 2.4mg weekly doses reached through gradual titration. Early weeks involve much lower doses. Dramatic week-one results vary significantly between individuals.
• Compounded semaglutide products are not equivalent to brand-name Wegovy or Ozempic. Formulation, concentration, and excipients differ. This is not a minor point.

Social media weight loss content moves fast. One person's week-one experience, even a genuine one, is not a clinical data point. It's anecdote. Useful context, not evidence.

The bottom line

The appetite suppression claim is scientifically grounded. The binge-eating framing deserves more caution. The video's real gap is what it leaves out: side effect profile, dose context, and the difference between reduced hunger and treated disordered eating. If you're considering semaglutide, those gaps matter more than a good week-one caption.